HLA Loss and the Impact on Immunotherapy

12/27/20 • 21 min

Loss of the HLA locus impairs presentation of tumor antigens and is frequently found in advanced cancers. This talk presented by Dr Lee Albacker, Foundation Medicine and first recorded at the 2020 IO360° Summit, will describe the landscape of HLA loss and other response biomarkers in a dataset of 90,000 solid tumor samples and highlight the effect of HLA loss on checkpoint inhibitor response. To learn more about the upcoming IO360° 2021 Summit please visit www.io360summit.com

Previous Episode

Cell & Gene Therapy Debate: Intrinsic Editing vs Systemic Combination

In this podcast first recorded at the 2020 IO360° Summit, Dr Aiman Shalabi, GSK, moderated a cell and gene therapy debate on intrinsic editing vs systemic combination Participants included: Mark O’Hara, MD, University of PennsylvaniaSaul Priceman, PhD, City of Hope To learn more about the upcoming IO360° 2021 Summit please visit www.io360summit.com

Next Episode

Innovations & Novel Approaches in IO Imaging & Assessing Responses

In this podcast, you will hear a panel discussion moderated by Dr Annette Schmid, Takeda Pharmaceuticals from the 2020 IO360° Summit regarding innovations and novel approaches in IO imaging and assessing responses. Panelists inclue: Gregory Goldmacher, MD, PhD, MBA, MerckS. Peter Eggleton, MD, FFPM, Merck KGaARon Korn, MD, PhD, Imaging EndpointsMatthew Silva, PhD, Invicro To learn more about the upcoming 2021 IO360° Summit please visit www.io360summit.com